Evaxion Biotech AS (EVAX) - Total Liabilities
Based on the latest financial reports, Evaxion Biotech AS (EVAX) has total liabilities worth $9.85 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check EVAX asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Evaxion Biotech AS - Total Liabilities Trend (2017–2025)
This chart illustrates how Evaxion Biotech AS's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see how large is Evaxion Biotech AS's balance sheet.
Evaxion Biotech AS Competitors by Total Liabilities
The table below lists competitors of Evaxion Biotech AS ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
DIAMINES AND CHEMICALS ORD (BSE)
NSE:DIAMINESQ
|
India | Rs169.43 Million |
|
Hidropar Hareket Kontrol Teknolojileri Merkezi Sanayi ve Ticaret A.S.
IS:HKTM
|
Turkey | TL827.76 Million |
|
Connexa Sports Technologies Inc.
NASDAQ:YYAI
|
USA | $6.75 Million |
|
Argent Minerals Ltd
AU:ARD
|
Australia | AU$463.67K |
|
UMediC Group Berhad
KLSE:0256
|
Malaysia | RM11.72 Million |
|
Park Street A/S
CO:PARKST-A
|
Denmark | Dkr1.45 Billion |
|
Kyobo 8 Special Purpose Acquisition Company
KQ:307280
|
Korea | ₩9.21 Billion |
|
Avalon Advanced Materials Ltd
TO:AVL
|
Canada | CA$5.35 Million |
Liability Composition Analysis (2017–2025)
This chart breaks down Evaxion Biotech AS's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See how leveraged is Evaxion Biotech AS's balance sheet to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.06 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.03 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.51 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Evaxion Biotech AS's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Evaxion Biotech AS (2017–2025)
The table below shows the annual total liabilities of Evaxion Biotech AS from 2017 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $11.37 Million | -19.58% |
| 2024-12-31 | $14.14 Million | -19.76% |
| 2023-12-31 | $17.62 Million | +28.39% |
| 2022-12-31 | $13.72 Million | +77.61% |
| 2021-12-31 | $7.73 Million | +56.81% |
| 2020-12-31 | $4.93 Million | +186.12% |
| 2019-12-31 | $1.72 Million | -81.77% |
| 2018-12-31 | $9.44 Million | +2266.92% |
| 2017-12-31 | $399.00K | -- |
About Evaxion Biotech AS
Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of advanced melanoma; EVX-03, DNA-based cancer vaccine for the treatment of solid tumors; and EVX-04, a therapeutic cancer vaccine candidate, which is in phase 1 trial for acute myeloid le… Read more